Literature DB >> 7747802

Decreased expression of Ras GTPase activating protein in human trophoblastic tumors.

M Ståhle-Bäckdhal1, M Inoue, J Zedenius, B Sandstedt, L DeMarco, F Flam, C Silfverswärd, J Andrade, E Friedman.   

Abstract

The normally developing placenta undergoes extensive but regulated noninvasive cellular proliferation. Various proto-oncogenes and growth factors have been associated with the regulation of trophoblastic placental growth. Activation of some oncogenes and altered expression of growth factors have been demonstrated in trophoblastic tumors (hydatidiform mole and choriocarcinoma). The ras proto-oncogene plays a key role in the signal transduction cascade of activated growth factors, and is known to be activated or overexpressed in multiple tumor types. Ras GTPase activating protein (RasGAP), a major down-regulator of ras activity, is present at high levels in placenta. To assess the role that Ras-GAP plays in the development of trophoblastic tumors, we performed immunohistochemical analyses with anti RasGAP antibodies of normal placentas, hydatidiform moles, invasive moles, and malignant choriocarcinomas. Normal placentas and noninvasive hydatidiform mole displayed intense positive staining confined to trophoblasts, whereas no staining was observed in the trophoblasts of invasive moles or choriocarcinomas. Thus, there was an inverse correlation between expression levels of RasGAP protein and the invasive potential and malignant phenotype in human trophoblastic tumors. The data indicate that RasGAP may play a regulatory role in trophoblast proliferation and that abolishing its activity may be associated with malignant transformation of these cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747802      PMCID: PMC1869290     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.

Authors:  M Trahey; F McCormick
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

2.  Demonstration by in situ hybridization of ret proto-oncogene mRNA in developing placenta during mid-term of rat gestation.

Authors:  Z Szentirmay; Y Ishizaka; H Ohgaki; T Tahira; M Nagao; H Esumi
Journal:  Oncogene       Date:  1990-05       Impact factor: 9.867

Review 3.  Differential imprinting and expression of maternal and paternal genomes.

Authors:  D Solter
Journal:  Annu Rev Genet       Date:  1988       Impact factor: 16.830

Review 4.  Growth factors, protooncogenes and human placental development.

Authors:  R Ohlsson
Journal:  Cell Differ Dev       Date:  1989-10

5.  The neurofibromatosis type 1 gene encodes a protein related to GAP.

Authors:  G F Xu; P O'Connell; D Viskochil; R Cawthon; M Robertson; M Culver; D Dunn; J Stevens; R Gesteland; R White
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

Review 6.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

7.  Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain.

Authors:  H Adari; D R Lowy; B M Willumsen; C J Der; F McCormick
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

8.  Suppression of c-ras transformation by GTPase-activating protein.

Authors:  K Zhang; J E DeClue; W C Vass; A G Papageorge; F McCormick; D R Lowy
Journal:  Nature       Date:  1990-08-23       Impact factor: 49.962

9.  Purification, characterization, and western blot analysis of human GTPase-activating protein from native and recombinant sources.

Authors:  R Halenbeck; W J Crosier; R Clark; F McCormick; K Koths
Journal:  J Biol Chem       Date:  1990-12-15       Impact factor: 5.157

10.  Cloning of bovine GAP and its interaction with oncogenic ras p21.

Authors:  U S Vogel; R A Dixon; M D Schaber; R E Diehl; M S Marshall; E M Scolnick; I S Sigal; J B Gibbs
Journal:  Nature       Date:  1988-09-01       Impact factor: 49.962

View more
  7 in total

1.  Power of the eternal youth: Nanog expression in the gestational choriocarcinoma.

Authors:  Ie-Ming Shih; Kuan-Ting Kuo
Journal:  Am J Pathol       Date:  2008-08-28       Impact factor: 4.307

2.  Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma.

Authors:  Wei-Cheng Xue; Kelvin Y K Chan; Hui-Chen Feng; Pui-Man Chiu; Hextan Y S Ngan; Sai-Wah Tsao; Annie N Y Cheung
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

3.  Establishment of a choriocarcinoma model from immortalized normal extravillous trophoblast cells transduced with HRASV12.

Authors:  Yusuke Kobayashi; Takatsune Shimizu; Hideaki Naoe; Arisa Ueki; Joe Ishizawa; Tatsuyuki Chiyoda; Nobuyuki Onishi; Eiji Sugihara; Osamu Nagano; Kouji Banno; Shinji Kuninaka; Daisuke Aoki; Hideyuki Saya
Journal:  Am J Pathol       Date:  2011-07-23       Impact factor: 4.307

4.  Genome-wide screening and co-expression network analysis identify recurrence-specific biomarkers of esophageal squamous cell carcinoma.

Authors:  Zong-wu Lin; Jie Gu; Rong-hua Liu; Xiao-ming Liu; Feng-kai Xu; Guang-yin Zhao; Chun-lai Lu; Di Ge
Journal:  Tumour Biol       Date:  2014-08-03

5.  Nuclear beta-catenin and Ki-67 expression in choriocarcinoma and its pre-malignant form.

Authors:  S C C Wong; A T C Chan; J K C Chan; Y M D Lo
Journal:  J Clin Pathol       Date:  2006-02-07       Impact factor: 3.411

6.  Reduced expression of neurofibromin in human meningiomas.

Authors:  V Sundaram; J H Lee; J A Harwalkar; D J Stein; M Roudebush; D W Stacey; M Golubic
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line.

Authors:  Shawna L Organ; Josephine Hai; Nikolina Radulovich; Christopher B Marshall; Lisa Leung; Takehiko Sasazuki; Senji Shirasawa; Chang-Qi Zhu; Roya Navab; Mitsuhiko Ikura; Ming-Sound Tsao
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.